Abstract
Background: Protein kinase C (PKC) has been linked to cardiomyocyte hypertrophy. However, the exact role of different PKC isoforms in mediating the hypertrophic response remains controversial and both classical and novel isoforms have been suggested to play a critical role. The aim of this study was to characterize the role of PKC isoforms in cardiomyocyte hypertrophy using pharmacological tools and high content screening (HCS). Methods: Neonatal rat ventricular cardiomyocytes (NRVCs) isolated from 1-3 days old Wistar rats and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) differentiated from iPS(IMR90)-4 line were exposed to endothelin-1 (ET-1) and PKC modulators for 48 h followed by fixing and immunofluorescence staining for nuclei, α-actinin and F-actin. Imaging and morphological analysis of thousands of cells were carried out using automated HCS platform. Results: NRVCs exposed to ET-1 (100 nM) or PKC agonists (HMI-1b11 at 10 μM or bryostatin-1 at 10 nM) or inhibitor of classical PKC isoforms, Gö6976 (1 μM), showed a hypertrophic phenotype measured by increased area and number of alpha-actinin and F-actin fibers in HCS. In contrast, inhibition of all PKC isoforms with Gö6983 (1 μM) attenuated ET-1 and PKC agonist-induced hypertrophy similarly to mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126 (10 μM). In turn, these HCS parameters did not show ET-1 or PKC agonist -induced hypertrophy in hiPSC-CMs. However, qRT-PCR analysis of the expression of NPPA and NPPB genes showed hypertrophic responses to ET-1 and PKC agonists also in hiPSC-CMs. Conclusions: These results confirm the central role of PKC in cardiomyocyte hypertrophy and indicate that either classical PKC isoforms have a direct anti-hypertrophic role in cardiomyocytes or, when classical PKCs are inhibited, the balance is moved towards activation of novel isoforms, which mediate the hypertrophic response. Due to the morphological differences between NRVCs and hiPSC-CMs, similar phenotypic analysis readouts cannot be reliably applied to compare hypertrophic responses in these cell types. These findings may help in developing new drugs that target specific PKC isoforms to treat cardiac hypertrophy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
